As per DelveInsight’s assessment, globally, about 100+ pharma and biotech companies are working on 130+ pipeline drugs in the Weight Loss/Weight Management (Obesity) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Common treatments for overweight and obesity include healthy eating, being more physically active, and changing the usual habits. Weight-management programs may help some people lose weight or keep from regaining lost weight. Some people who have obesity are unable to lose enough weight to improve their health, or are unable to keep from regaining weight. In such cases, a doctor may consider adding other treatments, including weight-loss medicines, weight-loss devices, or bariatric surgery.
“Weight Loss/Weight Management (Obesity) Pipeline Insight, 2023” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Weight Loss/Weight Management (Obesity) Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Weight Loss/Weight Management (Obesity) Pipeline Analysis
The report provides insights into:
– The report provides detailed insights into the key companies that are developing therapies in the Weight Loss/Weight Management (Obesity) Market.
– The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Weight Loss/Weight Management (Obesity) treatment.
– It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Weight Loss/Weight Management (Obesity) market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More About the Emerging Therapies and Evolving Treatment Algorithms:
The Report Covers the 130+ Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Route of Administration
The Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs, such as –
Obesity Products have been Categorized Under Various Molecule Types, such as –
– Monoclonal Antibody
– Small molecule
– Gene therapy
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
Weight Loss/Weight Management (Obesity) Therapeutics Analysis
There are approx. 100+ key companies developing therapies for Obesity. Currently, Novo Nordisk has its Obesity drug candidates in the most advanced stage of clinical development among all the key players.
Leading Companies in the Weight Loss/Weight Management (Obesity) Therapeutics Market
Some of the key companies in the Obesity Market include 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd. , Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.
Weight Loss/Weight Management (Obesity) Drugs Covered in the Report Include:
– Semaglutide oral: Novo Nordisk
– Tirzepatide: Eli Lilly and Company
– Tesomet: Saniona
– RZL-012: Raziel Therapeutics
– CT-868: Carmot Therapeutics
– EMP16: Empros Pharma
– DD01: D&D Pharmatech
– ZP 8396: Zealand Pharma
– ERX-1000: ERX Pharmaceuticals
– Boehringer Ingelheim: BI 456906.
– IBI362: Innovent Biologics (Suzhou) Co. Ltd.
– PYY 1875: Novo Nordisk A/S
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
Table of Content
1. Report Introduction
2. Executive Summary
3. Weight Loss/Weight Management (Obesity) Current Treatment Patterns
4. Weight Loss/Weight Management (Obesity) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Weight Loss/Weight Management (Obesity) Late-Stage Products (Phase-III)
7. Weight Loss/Weight Management (Obesity) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Weight Loss/Weight Management (Obesity) Discontinued Products
13. Weight Loss/Weight Management (Obesity) Product Profiles
14. Weight Loss/Weight Management (Obesity) Key Companies
15. Weight Loss/Weight Management (Obesity) Key Products
16. Dormant and Discontinued Products
17. Weight Loss/Weight Management (Obesity) Unmet Needs
18. Weight Loss/Weight Management (Obesity) Future Perspectives
19. Weight Loss/Weight Management (Obesity) Analyst Review
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
Manager – Marketing & International Branding
Email: [email protected]
Address: 428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.